Formulation of biotech products, including biopharmaceutical considerations

Pharmaceutical Biotechnology: Fundamentals and Applications, Third Edition

Volumn , Issue , 2016, Pages 67-94

  Crommelin, Daan J A ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LYGATURE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85051765641     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (72)

1. Arakawa T, Kita Y, Carpenter JF (1991). Protein-solvent interactions in pharmaceutical formulation. Pharmaceut Res, 8:285-91.
2. Banerjee PS, Hosny EA and Robinson JR (1991). Parenteral delivery of peptide and protein drugs. In Lee VHL, ed. Peptide and Protein Drug Delivery. New York:Marcel Dekker, 487-543.
3. Björk E, Edman P (1988). Characterization of degradable starch microspheres as a nasal delivery system for drugs. Int J Pharm, 62:187-92.
4. Brange J, Langkjaer L (1993). Insulin structure and stability. In: Wang YJ, Pearlman R, eds. Stability and Characterization of Protein and Peptide Drugs. Case Histories. New York: Plenum Press, 315-50.
5. Chien YW (1991). Transdermal route of peptide and protein drug delivery. In: Lee VHL, ed. Peptide and Protein Drug Delivery. New York: Marcel Dekker, 667-89.
6. Crommelin DJA, Bergers J, Zuidema J (1992). Antibodybased drug targeting approaches: perspectives and challenges. In: Wermuth CG, Koga N, König H, Metcalf BW, eds. Medicinal Chemistry for the 21st Century. Oxford: Blackwell Scientific Publications, 351-65.
7. Crommelin DJA, Scherphof G, Storm G (1995). Active targeting with particulate carrier systems in the blood compartment. Adv Drug Deliv Rev, 17:49-60.
8. Crommelin DJA, Schreier H (1994). Liposomes. In: Kreuter J, ed. Colloidal Drug Delivery Systems. New York:Marcel Dekker, 73-190.
9. Crommelin DJA, Storm G (1990). Drug Targeting. In:Sammes PG, Taylor JD, eds. Comprehensive Medicinal Chemistry. Oxford: Pergamon Press, 661-701.
10. Cullander C, Guy RH (1992) Transdermal delivery of peptides and proteins. Adv Drug Deliv Rev, 8:291-329.
11. De Leij L, De Jonge MWA, Ter Haar J, et al. (1990). Bispecific monoclonal antibody (BIAB) retargeted cellular therapy for local treatment of cancer patients. In: Crommelin DJA, Schellekens H, eds. From Clone to Clinic. Dordrecht: Kluwer Academic, 159-65.
12. Edman P, Björk E (1992). Nasal delivery of peptide drugs. Adv Drug Deliv Rev 8:165-77.
13. Eldridge JH, Hammond CJ, Meulbroek, JA, Staas JK, Giley RM, Tice TR (1990). Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J Control Rel 11:205-14.
14. Emmen F, Storm G (1987). Liposomes in the treatment of infectious diseases. Pharm Weekblad Sci Ed 9:162-71.
15. FDA, www.fda.gov/cber/vaccine/thimfaq.htm, 2006
16. Fanger MW, Guyre PM (1991). Bispecific antibodies for targeted cellular cytotoxicity. TIBTECH 9:375-80.
17. Fendler JH (1980). Optimizing drug entrapment in liposomes. Chemical and biophysical considerations. In:Gregoriadis G, Allison AC, eds. Liposomes in Biological Systems. Chichester: Wiley, J. & Sons, 87.
18. Franks F, Hatley RHM, Mathias SF (1991). Materials science and the production of shelf-stable biologicals. Pharmaceut Technol Int, 3.
19. Groves M (1988). Parenteral Technology Manual. Buffalo Grove, IL: Interpharm Press, Inc.
20. Halls NA (1994). Achieving Sterility in Medical and Pharmaceutical Products. New York: Marcel Dekker.
21. Heilmann K (1984). Therapeutic Systems. Rate Controlled Delivery: Concept and Development. Stuttgart: G. Thieme Verlag.
22. Heller J (1993). Polymers for controlled parenteral delivery of peptides and proteins. Adv Drug Deliv Rev 10:163-204.
23. Hellström KE, Hellström I, Goodman GE (1987). Antibodies for drug delivery. In: Robinson JR, LeeVHL, eds. Controlled Drug Delivery. New York: Marcel Dekker, 623-53.
24. Ho NFH, Barsuhn CL, Burton PS, Merkle HP (1992). Mechanistic insights to buccal delivery of proteinaceous substances. Adv Drug Deliv Rev 8:197-235.
25. Holmgren J, Clemens J, Sack D, Sanchez J, Svennerholm AM (1989). Development of oral vaccines with special reference to cholera. In: Breimer DD, Crommelin DJA, Midha KK, eds. Topics in Pharmaceutical Sciences. The Hague: International Pharmaceutical Federation (FIP), 297-311.
26. Hunt CA, MacGregor RD, Siegel RA (1986). Engineering targeted in vivo drug delivery. I. The physiological and physicochemical principles governing opportunities and limitations. Pharm Res 3:333-44.
27. Jain RK (1987). Transport of molecules in the tumor interstitium: A review. Cancer Res 47:3039-51.
28. Jani PU, Florence AT, McCarthy DE (1992). Further histological evidence of the gastrointestinal absorption of polystyrene nanospheres in the rat. Int J Pharm 84:245-52.
29. Kersten G, Hirschberg H (2004). Antigen delivery systems. Expert Rev. Vaccin 3:89-99.
30. Kim SW, Pai CM, Makino K, et al. (1990). Self-regulated glycosylated insulin delivery. J Control Rel 11:193-201.
31. Klegerman ME, Groves MJ (1992). Pharmaceutical Biotechnology: Fundamentals and Essentials. Buffalo Grove, IL: Interpharm Press.
32. Kumar S, Char H, Patel S, et al. (1992). In vivo transdermal iontophoretic delivery of growth hormone releasing factor GRF (1-44) in hairless guinea pigs. J Control Rel 18:213-20.
33. Lee VHL, Dodda-Kashi S, Grass GM, Rubas W (1991). Oral route of peptide and protein drug delivery. In: Lee VHL, ed. Peptide and Protein Drug Delivery. New York: Marcel Dekker, 691-738.
34. Lee HJ, Riley G, Johnson O, et al. (1997). In vivo characterization of sustained-release formulations of human growth hormone. J Pharmacol Exp Therapeut 281:1431-9.
35. Maberly GF, Wait GA, Kilpatrick JA, et al. (1982). Evidence for insulin degradation by muscle and fat tissue in an insulin resistant diabetic patient. Diabetologica 23:333-6.
36. Mastrobattista E, Aa MAEM, van der, Hennink WE, Crommelin DJA (2006). Artificial viruses: A nanotechnological approach to gene delivery. Nat Rev/Drug Dis 5:115-21.
37. Matthews SJ, McCoy C (2004). Peginterferon Alfa-2a: A review of approved and investigational use. Clin Therapeut 26:991-1024.
38. Nässander UK, Storm G, Peeters PAM, Crommelin DJA (1990). Liposomes. In: Chasin M, Langer R, eds. Biodegradable Polymers as Drug Delivery Systems. New York: Marcel Dekker, 261-33.
39. O'Hagan DT (1990). Intestinal translocation of particulates- implications for drug and antigen delivery. Adv Drug Deliv Rev 5:265-85.
40. Nguyen TH, Ward C (1993). Stability characterization and formulation development of alteplase, a recombinant tissue plasminogen activator. In:Wang YJ, Pearlman R, eds. Stability and Characterization of Protein and Peptide Drugs. Case Histories. New York: Plenum Press, 91-134.
41. Patton JS, Platz RM (1992). Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Deliv Rev 8:179-96.
42. Patton JS, Trinchero P, Platz RM (1994). Bioavailability of pulmonary delivered peptides and proteins: Alphainterferon, calcitonins and parathyroid hormones. J Control Release 28:79-85.
43. Patton JS, Bukar J, Nagarajan S (1999). Inhaled insulin. Adv Drug Deliv Rev 35:235-47.
44. Patton JS, Bukar JG, Eldon MA (2004). Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 43:781-801.
45. Pearlman R, Bewley TA (1993). Stability and characterization of human growth hormone. In: Wang YJ, Pearlman R, eds. Stability and Characterization of Protein and Peptide Drugs. Case Histories. New York:Plenum Press, 1-58.
46. Peeters PAM, Storm G, Crommelin DJA (1987). Immunoliposomes in vivo: State of the art. Adv Drug Deliv Rev 1:249-66.
47. Pikal MJ (1990a). Freeze-drying of proteins. Part I: Process Design. BioPharm 3(8):18-27.
48. Pikal MJ (1990b). Freeze-drying of proteins. Part II:Formulation selection. BioPharm 3:26-30.
49. Poste G (1985). Drug targeting in cancer therapy. In:Gregoriadis G, Poste G, Senior J, Trouet A, eds. Receptor-Mediated Targeting of Drugs. New York:Plenum Press, 427-74.
50. Pristoupil TI (1985). Haemoglobin lyophilized with sucrose:Effect of residual moisture on storage. Haematologia 18:45-52.
51. Ramakrishnan S (1990). Current status of antibody-toxin conjugates for tumor therapy. In: Tyle P, Ram BP, eds. Targeted Therapeutic Systems. New York: Marcel Dekker, 189-213.
52. Roitt IM, Brostoff J, Male DK (1993). Immunology. 3rd ed. St. Louis, MO: Mosby.
53. Sage BH, Bock CR, Denuzzio JD, Hoke RA (1995). Technological and developmental issues of iontophoretic transport of peptide and protein drugs. In:Lee VHL, Hashida M, Mizushima Y, eds. Trends and Future Perspectives in Peptide and Protein Drug Delivery. Chur: Harwood Academic Publishers GmbH, 111-34.
54. Soon-Shiong P, Heintz RE, Merideth N, et al. (1994). Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet 343:950-51.
55. Stenekes R (2000). Nanoporous dextran microspheres for drug delivery. Thesis, Utrecht University.
56. Storm G, Oussoren C, Peeters PAM, Barenholz YB (1993). Tolerability of liposomes in vivo. In: Gregoriadis G, ed. Liposome Technology. Boca Raton, FL: CRC Press, 345-83.
57. Storm G, Nässander U, Vingerhoeds MH, Steerenberg PA, Crommelin DJA (1994). Antibody-targeted liposomes to deliver doxorubicin to ovarian cancer cells. J Liposome Res 4:641-66.
58. Storm G, Crommelin DJA (1998). Liposomes: Quo vadis? Pharmaceut Sci Technol Today 1:19-31.
59. Supersaxo A, Hein WR, Steffen H (1990). Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7:167-9.
60. Thurow H, Geisen K (1984). Stabilization of dissolved proteins against denaturation at hydrophobic interfaces. Diabetologica 27:212-8.
61. Tomlinson E (1987). Theory and practice of site-specific drug delivery. Adv Drug Deliv Rev 1:87-198.
62. Toonen P, Crommelin DJA (1983). Immunogobulins as targeting agents for liposome encapsulated drugs. Pharm Weekblad Sci Ed 16:269-80.
63. Tresco PA (1994). Encapsulated cells for sustained neurotransmitter delivery to the central nervous system. J Control Rel 28:253-8.
64. Uludag H, Kharlip L, Sefton MV (1993). Protein delivery by microencapsulated cells. Adv Drug Deliv Rev 10:115-30.
65. USP 29/NF 24 through second supplement (2006). Rockville, MD: United States Pharmacopeial Convention, Inc.
66. van Dijkhuizen-Radersma R, Wright SJ, Taylor LM, John BA, de Groot K, Bezemer JM (2004). In vitro/in vivo correlation for 14C-methylated lysozyme release from poly(ether-ester) microspheres. Pharm Res 21:484-91.
67. Vemuri S, Yu CT, Roosdorp N (1993a). Formulation and stability of recombinant alpha-antitrypsin. In: Wang YJ, Pearlman R, eds. Stability and Characterization of Protein and Peptide Drugs. Case Histories. New York:Plenum Press, 263-86.
68. Vemuri S, Yu CT, Roosdorp N (1993b). Formulation and stability of recombinant alpha1-antitrypsin. In: Wang YJ, Pearlman R, eds. Stability and Characterization of Protein and Peptide Drugs. New York: Plenum Press, 263-86.
69. Vingerhoeds MH, Storm G, Crommelin DJA (1994). Immunoliposomes in vivo. Immunomethods 4:259-72.
70. Woodle M, Newman M, Collins L, Redemann C, Martin F (1990). Improved long-circulating (Stealth®) liposomes using synthetic lipids. Proc Int Symp Control Rel Bioactive Mater 17:77-8.
71. Zhou XH, LiWan Po A (1991a). Peptide and protein drugs: I. Therapeutic applications, absorption and parenteral administration. Int J Pharm 75:97-115.
72. Zhou XH, Li Wan Po A (1991b). Peptide and protein drugs:II. Non-parenteral routes of delivery. Int J Pharm 75:117-30.